Patient
SITE013-0232
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE013 (USA) (Dr. Clarke)
consented 2026-06-07
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-13 (study day 93); relationship: not assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-03-07 (study day 87); relationship: not assessed
Grade 2 Rash — outcome: RECOVERED/RESOLVED; onset 2023-03-06 (study day 86); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 51); relationship: not assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-22 (study day 43); relationship: RELATED
Grade 3 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-01-14 (study day 35); relationship: not assessed; serious criteria: hospitalization
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-22 (study day 12); relationship: RELATED
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-12-19 (study day 9); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.